Product image of No-Spa (Drotaverine Hydrochloride) supplied by GNH India

No-Spa

Active Ingredient:
Drotaverine Hydrochloride
Origin:
EU

No-Spa (Drotaverine Hydrochloride)

Drotaverine Hydrochloride, the active ingredient in No‑Spa, is a phosphodiesterase inhibitor presented as an injectable solution for intramuscular and intravenous administration. It produces smooth‑muscle relaxation and is used to alleviate abdominal and gastrointestinal spasms, biliary and renal colic, dysmenorrhea, and urinary tract spasm in adult patients.

GNH India supplies No‑Spa as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under strict quality‑assurance standards and supports regulatory compliance for each market through dedicated logistics and technical assistance.

Manufacturer / TM Owner

Opella Healthcare Commercial Kft.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

No‑Spa acts on smooth‑muscle spasm disorders, providing relief in several gastrointestinal and urogenital conditions.

  • Abdominal and gastrointestinal spasms: reduces pain and restores normal motility.
  • Biliary colic: relaxes biliary ducts to ease stone‑related pain.
  • Renal colic: alleviates ureteral smooth‑muscle contraction.
  • Dysmenorrhea: diminishes uterine muscle cramps during menstruation.
  • Urinary tract spasm: eases bladder and urethral smooth‑muscle irritation.

How It Works

  • Drotaverine Hydrochloride inhibits phosphodiesterase enzymes, leading to increased intracellular cyclic AMP levels. Elevated cAMP promotes smooth‑muscle relaxation by reducing calcium influx and directly blocking calcium channels, resulting in decreased contractility of gastrointestinal, biliary, urinary, and uterine smooth muscle.

Side Effects

Adverse reactions may occur with any antispasmodic therapy.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Nausea: transient feeling of queasiness.
  • Dizziness: occasional light‑headedness.
  • Flushing: temporary redness of the skin.
  • Hypotension: mild drop in blood pressure.

Serious or Rare Side Effects

  • Anaphylactic reaction: severe allergic response requiring immediate medical attention.
  • Severe hypotension: marked blood pressure decrease leading to fainting.
  • Cardiac arrhythmia: irregular heart rhythm.
  • Hepatic dysfunction: abnormal liver enzyme elevations.
  • Blood dyscrasias: rare blood cell abnormalities.

Precautions & Warnings

Safety considerations should be observed before and during treatment.

  • Pregnancy: safety not established; use only if clearly needed and prescribed.
  • Breastfeeding: weigh potential risks against benefits; consult a physician.
  • Renal impairment: monitor renal function and adjust therapy as needed.
  • Concomitant antihypertensives: observe for additive blood‑pressure lowering effects.
  • Known hypersensitivity: avoid use in patients with documented allergy to drotaverine or excipients.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Potential drug interactions may modify therapeutic outcomes.

Major Interactions (Avoid)

  • Potent vasodilators: combined use can cause severe hypotension.
  • Other phosphodiesterase inhibitors: may increase risk of cardiovascular side effects.
  • Strong CYP450 inhibitors: could raise drotaverine plasma concentrations.

Moderate Interactions (Monitor Closely)

  • Antihypertensive agents: monitor blood pressure for additive effects.
  • Diuretics: watch for electrolyte disturbances and blood‑pressure changes.
  • Additional antispasmodics: assess for cumulative smooth‑muscle relaxation.

Frequently Asked Questions

No‑Spa (drotaverine hydrochloride) is prescribed to relieve smooth‑muscle spasms such as abdominal and gastrointestinal colic, biliary colic, renal colic, menstrual cramps (dysmenorrhea), and urinary tract spasm in adult patients.

Drotaverine blocks phosphodiesterase enzymes, raising intracellular cAMP levels, which relaxes smooth muscle. It also exhibits calcium‑channel blocking activity, further reducing muscle contraction and easing spasm‑related pain.

The dosage of No‑Spa is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, and route of administration. Specific dosing regimens should follow the healthcare professional’s instructions.

Safety data for drotaverine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk, and the decision must be made by a qualified healthcare provider.

To request No‑Spa, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and import documentation.

Compared with anticholinergic antispasmodics, drotaverine offers smooth‑muscle relaxation without significant anticholinergic side effects such as dry mouth or blurred vision. Its dual action on phosphodiesterase inhibition and calcium channels provides rapid relief of spasm.

No‑Spa should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze the product or shake the vial vigorously, and keep it in the original packaging until use.

No‑Spa is supplied as an injectable solution and can be given either intramuscularly or intravenously by a qualified healthcare professional, following aseptic technique and appropriate dosing guidelines.

Serious risks include severe allergic reactions (anaphylaxis), marked hypotension, cardiac arrhythmias, hepatic dysfunction, and rare blood‑cell abnormalities. Patients should be monitored for these events, especially after the first dose.

No‑Spa is contraindicated in individuals with known hypersensitivity to drotaverine or any excipients in the formulation. Caution is advised for patients with severe cardiovascular disease, uncontrolled hypertension, or significant liver impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Drotaverine Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT